SCHEMBL4500266

SCHEMBL4500266

COc1ccc(-c2sc(CNS(=O)(=O)c3c(F)cccc3F)cc2-c2ccc(Cl)cc2Cl)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.39
PGR P06401 2/20 0.38
NR3C1 P04150 1/20 0.38
MAPT P10636 4/20 0.38
KMT2A Q03164 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TSHR P16473 1/20 0.38
EP300 Q09472 1/20 0.37
ALDH1A1 P00352 2/20 0.37
POLB P06746 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
RXFP1 Q9HBX9 2/20 0.36
CYP19A1 P11511 1/20 0.36
MEN1 O00255 1/20 0.36
ACHE P22303 1/20 0.36
STAT3 P40763 1/20 0.36
TP53 P04637 2/20 0.36
GNRHR P30968 1/20 0.36
FLT1 P17948 1/20 0.35
FLT4 P35916 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4480858 0.90 KMT2A (0.41) CNR1PGRNR3C1MAPTKMT2A
SCHEMBL4490302 0.87 ALDH1A1 (0.41) CNR1PGRNR3C1MAPTKMT2A
SCHEMBL4492694 0.87 MAPT (0.41) CNR1MAPTKMT2ASMN1; SMN2ALDH1A1
SCHEMBL4505757 0.87 PGR (0.48) CNR1PGRMAPTKMT2ASMN1; SMN2
SCHEMBL4488977 0.86 MAPT (0.42) CNR1PGRNR3C1MAPTKMT2A
SCHEMBL4491425 0.86 FLT1 (0.47) PGRMAPTKMT2ASMN1; SMN2ALDH1A1
SCHEMBL4496378 0.86 MAPT (0.51) CNR1PGRNR3C1MAPTKMT2A
SCHEMBL4494987 0.85 ALDH1A1 (0.47) CNR1MAPTKMT2ASMN1; SMN2ALDH1A1
SCHEMBL4488378 0.85 MAPT (0.52) CNR1PGRNR3C1MAPTKMT2A
SCHEMBL4487171 0.83 KMT2A (0.46) CNR1KMT2ASMN1; SMN2TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589120-B2 N-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide derivatives, preparation thereof and their therapeutic application SANOFI-AVENTIS (FR) 2009-09-15 US claimed
US-20070287744-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-12-13 US claimed
US-7589120-B2 N-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide derivatives, preparation thereof and their therapeutic application SANOFI-AVENTIS (FR) 2009-09-15 US disclosed
US-20070287744-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287744-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION TPMT, TXNRD2, ARG2 CNR1 60/4885PGR 1037/4885NR3C1 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.